Objectif
NEURINOX aims at elucidating the role of NADPH oxidases (NOX) in neuroinflammation and its progression to neurodegenerative diseases (ND), as well as evaluating the potential of novel ND therapeutics approaches targeting NOX activity. NOX generate reactive oxygen species (ROS) and have emerged as regulators of neuroinflammation. Their role is complex: ROS generated by NOX lead to tissue damage in microglia-mediated neuroinflammation, as seen in amyotrophic lateral sclerosis (ALS), while absence of ROS generation enhances the severity of autoimmune-mediated neuroinflammation, as seen for e.g. in multiple sclerosis (MS).
The objective of the 5 years NEURINOX project is to understand how NOX controls neuroinflammation, identify novel molecular pathways and oxidative biomarkers involved in NOX-dependent neuroinflammation, and develop specific therapies based on NOX modulation. The scientific approach will be to: (i) identify NOX-dependent molecular mechanisms using dedicated ND animal models (ii) develop therapeutic small molecules either inhibiting or activating NOX and test their effects in animal models (iii) test the validity of identified molecular pathways in clinical studies in ALS and MS patients.
NEURINOX will contribute to better understand brain dysfunction, and more particularly the link between neuroinflammation and ND and to identify new therapeutic targets for ND. A successful demonstration of the benefits of NOX modulating drugs in ALS and MS animal models, and in ALS early clinical trials will validate a novel high potential therapeutics target for ALS and also many types of ND. NEURINOX has hence a strong potential for more efficient ND healthcare for patients and thus for reducing ND healthcare costs.
This multi-disciplinary consortium includes leading scientists in NOX research, ROS biology, drug development SMEs, experts in the neuroinflammatory aspects of ND, genomics and proteomics, and clinicians able to translate the basic science to the patient.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsproteomics
- medical and health sciencesbasic medicineneurologymultiple sclerosis
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsenzymes
- medical and health sciencesbasic medicineneurologyamyotrophic lateral sclerosis
Thème(s)
Appel à propositions
FP7-HEALTH-2011-two-stage
Voir d’autres projets de cet appel
Régime de financement
CP-IP - Large-scale integrating projectCoordinateur
1211 Geneve
Suisse
Voir sur la carte
Participants (14)
Participation terminée
38041 GRENOBLE
Voir sur la carte
8006 ZURICH
Voir sur la carte
74160 ARCHAMPS
Voir sur la carte
223 81 Lund
Voir sur la carte
75008 Paris
Voir sur la carte
10124 Torino
Voir sur la carte
17177 Stockholm
Voir sur la carte
38401 SAINT MARTIN D'HERES
Voir sur la carte
38330 SAINT ISMIER
Voir sur la carte
115 27 Athina
Voir sur la carte
10561 Athina
Voir sur la carte
Participation terminée
2006 Sydney
Voir sur la carte
1205 Geneve
Voir sur la carte
2010 DARLINGHURST
Voir sur la carte